Document is current

Any future updates will be listed below

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations

Crossref DOI link: https://doi.org/10.1038/s41571-025-01062-6

Published Online: 2025-07-22

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark